Combination of propofol and nasal sufentanil or intravenous midazolam for colonoscopy: a comparative study
Tulin Akarsu Ayazoglu, Sinan Uzman
Anaesthesiology Intensive Therapy · 2021
doi:10.5114/ait.2021.106298 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Introduction The aim of the study was to compare and evaluate the side effects (SEs) and sedation characteristics of synergistic sedation with doses of 0.25 μg kg-1 or 0.5 μg kg-1 intranasal (IN) sufentanil, and intravenous (IV) midazolam during propofol-based sedation in patients undergoing colonoscopy. Material and methods This was a prospective, randomized, double-blind study. The patients were randomly allocated into one of 3 groups: group I (n = 33) – sufentanil IN 0.5 μg kg–1; group II (n = 33) – sufentanil IN 0.25 μg kg-1; and group III (n = 33) – IN 0.9% NaCl ( placebo ) and IV 0.04 mg kg-1 midazolam. After 15 minutes, all patients received 0.5 mg kg-1 propofol intravenously. Cardiorespiratory side effects and sedation characteristics were compared. Results The propofol consumption in group III was significantly higher than in group I and II (P < 0.001). Spontaneous eye opening time was significantly longer in group III than in group I and II ( < 0.001). The patients in group III had significantly longer recovery times than patients in group I and II (P < 0.0001). Hypotension and bradycardia were not encountered during the study. The incidence of hypoxaemia was significantly greater in group III compared to other groups (P < 0.001). Pain control and endoscopist satisfaction was significantly better for group I and II than for group III (P < 0.001). Conclusions Synergistic sedation can be achieved safely and effectively by the combination of propofol and IN sufentanil or IV midazolam for colonoscopy. However, IN sufentanil can be considered as a reasonable alternative to IV midazolam due to less respiratory depression, and better pain control and endoscopist satisfaction.
Abstract licence: CC BY-NC-SA
References38
38 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.